指南与共识白血病MDS 与骨髓增殖性肿瘤

接受新型靶向治疗的成人急性髓系白血病患者的抗真菌预防:欧洲血液学协会系统综述与专家共识推荐

Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association.
指南 / 共识 · Lancet Haematol · 2022-01-01

欧洲血液学协会组织多学科专家,按 Cochrane 方法系统检索 MEDLINE、Embase 和 Cochrane Library(截至 2020 年 3 月 10 日),采用 GRADE 证据到决策框架,针对新型靶向药物治疗的成人急性髓系白血病患者制定抗真菌预防及三唑类药代动力学药物相互作用管理的推荐与共识声明。

要点

  • 多数情境下中等强度推荐抗真菌预防,新型药物联合强化诱导化疗时强推荐。
  • 对 hypomethylating agents、midostaurin 及 venetoclax-hypomethylating agent 组合给出循证推荐。
  • 对 ivosidenib、lestaurtinib、quizartinib 和 venetoclax,中等强度推荐在使用三唑类期间调整抗白血病药物剂量。

核心结论

  • 这是首个支持新型靶向药物治疗的急性髓系白血病患者抗真菌预防临床决策的指导文件。
  • 未来需纳入治疗药物监测的研究来确定新型抗白血病药物与抑制 CYP3A4 的抗真菌药联用时剂量调整对不良反应和缓解状态的作用。

研究设计与样本

  • 欧洲血液学协会委托感染性疾病、血液学、肿瘤学、临床药理学和方法学专家制定推荐。
  • 按 Cochrane 方法进行系统文献综述,检索 MEDLINE、Embase 和 Cochrane Library(含 CENTRAL)从建库至 2020 年 3 月 10 日发表的随机对照试验和系统综述。
  • 排除非英文发表的研究,采用 GRADE 证据到决策框架制定推荐。

主要发现

  • 对每种被识别的新型抗急性髓系白血病药物,就侵袭性真菌病发生率、住院延长、重症监护室天数、侵袭性真菌病所致死亡、生活质量和潜在药物相互作用等结局进行证据审查。
  • 针对 hypomethylating agents、midostaurin 和 venetoclax-hypomethylating agent 组合制定了循证推荐。
  • 对其他所有药物,针对复发或难治性急性髓系白血病、单药治疗及联合化疗等特定治疗情境给出共识声明。

关键数值与推荐

  • 大多数情境下中等强度推荐抗真菌预防。
  • 若新型急性髓系白血病药物与强化诱导化疗联合使用,则强推荐抗真菌预防。
  • 对 ivosidenib、lestaurtinib、quizartinib 和 venetoclax,中等强度推荐在使用三唑类期间调整抗白血病药物剂量。

临床怎么用

  • 对接受新型靶向药物治疗的成人急性髓系白血病患者,多数情境下中等强度推荐抗真菌预防。
  • 当新型急性髓系白血病药物与强化诱导化疗联合使用时,强推荐抗真菌预防。
  • 对使用 ivosidenib、lestaurtinib、quizartinib 或 venetoclax 的患者,中等强度推荐在使用三唑类抗真菌药期间调整抗白血病药物剂量。

局限性

  • 许多新型靶向药物经细胞色素 P450 代谢,但潜在药物相互作用及由此产生的风险获益比尚未在临床试验中评估。
  • 未来需纳入治疗药物监测的研究来确定新型抗白血病药物与抑制 CYP3A4 的抗真菌药联用时剂量调整对不良反应和缓解状态的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

On the basis of improved overall survival, treatment guidelines strongly recommend antifungal prophylaxis during remission induction chemotherapy for patients with acute myeloid leukaemia. Many novel targeted agents are metabolised by cytochrome P450, but potential drug-drug interactions (DDIs) and the resulting risk-benefit ratio have not been assessed in clinical trials, leading to uncertainty in clinical management. Consequently, the European Haematology Association commissioned experts in the field of infectious diseases, haematology, oncology, clinical pharmacology, and methodology to develop up-to-date recommendations on the role of antifungal prophylaxis and management of pharmacokinetic DDIs with triazole antifungals. A systematic literature review was performed according to Cochrane methods, and recommendations were developed by use of the Grading of Recommendations Assessment, Development and Evaluation Evidence to Decision framework. We searched MEDLINE, Embase, and Cochrane Library, including Central Register of Controlled Trials, for randomised controlled trials and systematic reviews published from inception to March 10, 2020. We excluded studies that were not published in English. Evidence for any identified novel agent that is active against acute myeloid leukaemia was reviewed for the following outcomes: incidence of invasive fungal disease, prolongation of hospitalisation, days spent in intensive-care unit, mortality due to invasive fungal disease, quality of life, and potential DDIs. Recommendations and consensus statements were compiled for each targeted drug for patients with acute myeloid leukaemia and each specific setting. Evidence-based recommendations were developed for hypomethylating agents, midostaurin, and the venetoclax-hypomethylating agent combination. For all other agents, consensus statements were given for specific therapeutic settings, specifically for the management of patients with relapsed or refractory acute myeloid leukaemia, monotherapy, and combination with chemotherapy. Antifungal prophylaxis is recommended with moderate strength in most settings, and strongly recommended if the novel acute myeloid leukaemia agent is administered in combination with intensive induction chemotherapy. For ivosidenib, lestaurtinib, quizartinib, and venetoclax, we moderately recommend adjusting the dose of the antileukaemic agent during administration of triazoles. This is the first guidance supporting clinical decision making on antifungal prophylaxis in recipients of novel targeted drugs for acute myeloid leukaemia. Future studies including therapeutic drug monitoring will need to determine the role of dosage adjustment of novel antileukaemic drugs during concomitant administration of CYP3A4-inhibiting antifungals with respect to adverse effects and remission status.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Stemler J, de Jonge N, Skoetz N, et al. Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association. Lancet Haematol. 2022. PMID: 35483397. doi:10.1016/S2352-3026(22)00073-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。